サンプル依頼リスト カート
  • English
  • Korean
  • Traditional Chinese
  • Simplified Chinese
デフォルト表紙
市場調査レポート
商品コード
1578246

アピキサバンの世界市場調査レポート：産業分析、規模、シェア、成長、動向、2024年～2032年の予測

Global Apixaban Market Research Report - Industry Analysis, Size, Share, Growth, Trends and Forecast 2024 to 2032

出版日
ページ情報
英文 129 Pages
納期
即日から翌営業日
カスタマイズ可能
価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=148.84円
アピキサバンの世界市場調査レポート：産業分析、規模、シェア、成長、動向、2024年～2032年の予測
出版日: 2024年09月01日
発行: Value Market Research
ページ情報: 英文 129 Pages
納期: 即日から翌営業日
GIIご利用のメリット
  • 全表示
  • 概要
  • 図表
  • 目次
概要

アピキサバン市場の世界需要は、2023年の173億6,000万米ドルから2032年には337億1,000万米ドル近くの市場規模に達すると推定され、調査期間2024-2032年のCAGRは7.65%です。

アピキサバンは、非弁膜症性心房細動患者の血栓および脳卒中の治療と予防に使用される抗凝固薬です。アピキサバンは血液をサラサラにする薬剤で、人工股関節置換術や人工膝関節置換術の後に血栓が形成され、肺に血栓（肺塞栓症）ができるのを防ぐことを目的としています。血液検査や食事制限が不要なため、ワルファリンの代わりに使用されます。アピキサバンは第Xa因子阻害薬に属します。アピキサバンは、血栓の形成を補助する天然物質を阻止することによって作用します。アピキサバンはEliquisという名前で販売されています。錠剤の形で経口投与されます。最も一般的な副作用は出血と吐き気です。妊娠中や授乳中にアピキサバンを服用することは推奨されません。軽度の腎障害のある人では、比較的安全に使用できるようです。Eliquisはワルファリンよりも相互作用の少ない薬です。

市場力学

アピキサバンの治療適応の増加、心房細動、静脈血栓塞栓症、脳卒中の有病率の増加が市場の成長に大きく寄与しています。さらに、高齢者人口の増加、肥満の有病率の増加が市場開拓を補完しています。さらに、世界のヘルスケア支出の急増や、ヘルスケアの研究開発に多額の投資を行う政府機関や民間機関の増加も、アピキサバン市場を牽引する重要な要因となっています。さらに、新興国における潜在力の高まり、ヘルスケア分野における技術の進歩と近代化の進展は、アピキサバン市場を拡大させると思われます。しかし、アピキサバンは、服用が早すぎると血栓イベントや出血のリスクが高まるなどの副作用があるため、使用が制限され、市場成長の妨げになる可能性が高いです。

調査レポートでは、ポーターのファイブフォースモデル、市場の魅力分析、バリューチェーン分析を取り上げています。これらのツールは、業界の構造を明確に把握し、世界レベルでの競合の魅力を評価するのに役立ちます。さらに、これらのツールはアピキサバンの世界市場における各セグメントを包括的に評価することもできます。アピキサバン業界の成長と動向は、本調査に全体的なアプローチを提供します。

ご要望がございましたら、弊社までご連絡ください。当社の調査チームは、お客様のニーズに応じてカスタマイズしたレポートを提供することができます。

目次

第1章 序文

第2章 エグゼクティブサマリー

  • 市場のハイライト
  • 世界市場スナップショット

第3章 アピキサバン-産業分析

  • イントロダクション：市場力学
  • 市場促進要因
  • 市場抑制要因
  • 市場機会
  • 業界動向
  • ポーターのファイブフォース分析
  • 市場の魅力分析

第4章 バリューチェーン分析

  • バリューチェーン分析
  • 原材料分析
    • 原材料リスト
    • 原材料メーカーリスト
    • 主要原材料の価格動向
  • 潜在的バイヤーリスト
  • マーケティングチャネル
    • ダイレクトマーケティング
    • インダイレクトマーケティング
    • マーケティングチャネル発展動向

第5章 アピキサバンの世界市場分析：剤形別

  • 概要
  • 実績および予測データ
  • 剤形別分析
  • カプセル
  • 錠剤

第6章 アピキサバンの世界市場分析：エンドユーザー別

  • 概要
  • 実績および予測データ
  • エンドユーザー別分析
  • 病院
  • 診療所
  • 小売薬局
  • オンライン薬局
  • その他

第7章 アピキサバンの世界市場分析：地域別

  • 地域別展望
  • イントロダクション
  • 北米売上分析
    • 概要、実績と予測
    • 北米セグメント別
    • 北米国別
    • 米国
    • カナダ
    • メキシコ
  • 欧州売上分析
    • 概要、実績と予測
    • 欧州セグメント別
    • 欧州国別
    • 英国
    • フランス
    • ドイツ
    • イタリア
    • ロシア
    • その他欧州
  • アジア太平洋地域売上分析
    • 概要、実績と予測
    • アジア太平洋地域セグメント別
    • アジア太平洋地域国別
    • 中国
    • インド
    • 日本
    • 韓国
    • オーストラリア
    • 東南アジア
    • その他アジア太平洋地域
  • ラテンアメリカ売上分析
    • 概要、実績と予測
    • ラテンアメリカセグメント別
    • ラテンアメリカ国別
    • ブラジル
    • アルゼンチン
    • ペルー
    • チリ
    • その他ラテンアメリカ
  • 中東・アフリカ売上分析
    • 概要、実績と予測
    • 中東・アフリカセグメント別
    • 中東・アフリカ国別
    • サウジアラビア
    • アラブ首長国連邦
    • イスラエル
    • 南アフリカ
    • その他中東とアフリカ

第8章 アピキサバン企業の競合情勢

  • アピキサバン市場の競合
  • 提携・協力・合意
  • 合併・買収
  • 新製品の上市
  • その他の開発

第9章 企業プロファイル

  • 上位企業の市場シェア分析
  • 市場集中度
  • F. Hoffmann-La Roche Ltd
  • Hikma Pharmaceuticals PLC
  • Eisai Co. Ltd
  • Sanofi S.A.
  • Yino Pharma Limited
  • Mylan N.V.
  • Bristol Myers Squibb Company
  • Abbott Laboratories
  • Hebei Changshan Biochemical Pharmaceutical Co. Ltd
  • Nanjing Jianyou Biochemical Pharmaceutical Co. Ltd.
  • Aspen Holdings
  • Fresenius Kabi AG
  • Pfizer Inc.
図表

LIST OF TABLES

  • Market Snapshot
  • Drivers: Impact Analysis
  • Restraints: Impact Analysis
  • List of Raw Material
  • List of Raw Material Manufactures
  • Analysis By Dosage Form (USD MN)
  • Capsule Market Sales By Geography (USD MN)
  • Tablet Market Sales By Geography (USD MN)
  • Analysis By End-User (USD MN)
  • Hospitals Market Sales By Geography (USD MN)
  • Clinics Market Sales By Geography (USD MN)
  • Retail Pharmacies Market Sales By Geography (USD MN)
  • Online Pharmacies Market Sales By Geography (USD MN)
  • Others Market Sales By Geography (USD MN)
  • Global Apixaban Market Sales By Geography (USD MN)
  • North America Market Analysis (USD MN)
  • United States Market Analysis (USD MN)
  • Canada Market Analysis (USD MN)
  • Mexico Market Analysis (USD MN)
  • Europe Market Analysis (USD MN)
  • Europe Market Estimate By Country (USD MN)
  • United Kingdom Market Analysis (USD MN)
  • France Market Analysis (USD MN)
  • Germany Market Analysis (USD MN)
  • Italy Market Analysis (USD MN)
  • Russia Market Analysis (USD MN)
  • Spain Market Analysis (USD MN)
  • Rest of Europe Market Analysis (USD MN)
  • Asia Pacific Market Analysis (USD MN)
  • China Market Analysis (USD MN)
  • Japan Market Analysis (USD MN)
  • India Market Analysis (USD MN)
  • South Korea Market Analysis (USD MN)
  • Australia Market Analysis (USD MN)
  • South East Asia Market Analysis (USD MN)
  • Rest of Asia Pacific Market Analysis (USD MN)
  • Latin America Market Analysis (USD MN)
  • Brazil Market Analysis (USD MN)
  • Argentina Market Analysis (USD MN)
  • Peru Market Analysis (USD MN)
  • Chile Market Analysis (USD MN)
  • Rest of Latin America Market Analysis (USD MN)
  • Middle East & Africa Market Analysis (USD MN)
  • Saudi Arabia Market Analysis (USD MN)
  • UAE Market Analysis (USD MN)
  • Israel Market Analysis (USD MN)
  • South Africa Market Analysis (USD MN)
  • Rest of Middle East and Africa Market Analysis (USD MN)
  • Partnership/Collaboration/Agreement
  • Mergers And Acquisition

LIST OF FIGURES

  • Research Scope of Apixaban Report
  • Market Research Process
  • Market Research Methodology
  • Global Apixaban Market Size, By Region (USD MN)
  • Porters Five Forces Analysis
  • Market Attractiveness Analysis By Dosage Form
  • Market Attractiveness Analysis By End-User
  • Market Attractiveness Analysis By Region
  • Value Chain Analysis
  • Global Market Analysis By Dosage Form (USD MN)
  • Capsule Market Sales By Geography (USD MN)
  • Tablet Market Sales By Geography (USD MN)
  • Global Market Analysis By End-User (USD MN)
  • Hospitals Market Sales By Geography (USD MN)
  • Clinics Market Sales By Geography (USD MN)
  • Retail Pharmacies Market Sales By Geography (USD MN)
  • Online Pharmacies Market Sales By Geography (USD MN)
  • Others Market Sales By Geography (USD MN)
  • Global Market Sales (USD MN)
  • North America Market Sales (USD MN)
  • Europe Market Sales (USD MN)
  • Asia Pacific Market Sales (USD MN)
  • Latin America Market Sales (USD MN)
  • Middle East & Africa Market Sales (USD MN)
  • Recent Development in Industry
  • Top Company Market Share Analysis

Kindly note that the above listed are the basic tables and figures of the report and are not limited to the TOC.

目次
Product Code: VMR11216577

The global demand for Apixaban Market is presumed to reach the market size of nearly USD 33.71 Billion by 2032 from USD 17.36 Billion in 2023 with a CAGR of 7.65% under the study period 2024-2032.

Apixaban is an anticoagulant drug used to treat and prevent blood clots and strokes in people with nonvalvular atrial fibrillation. Apixaban is a blood thinner that is intended to prevent blood clots from forming following hip or knee replacement surgery, which can lead to lungs blood clots (pulmonary embolism). It's used instead of warfarin because it doesn't require blood tests or dietary restrictions. Apixaban belongs to the factor Xa inhibitors class of drugs. It works by stopping a natural substance that assist in the formation of blood clots. Apixaban is marketed under the name Eliquis. It is taken orally in the form of tablets. The most common side effects are bleeding and nausea. It is not recommended to take apixaban while pregnant or breastfeeding. In people with mild renal issues, it appears to be relatively safe to use. Eliquis interacts with fewer medications than warfarin.

MARKET DYNAMICS

Rising therapeutic indications for apixaban, an increase in the prevalence of atrial fibrillation, venous thromboembolism, and stroke are substantially contributing to the market growth. Furthermore, an increase in the geriatric population, an increase in the prevalence of obesity are supplementing market development. Additionally, a rising surge in healthcare expenditures worldwide and increasing government and private organizations investing significantly in healthcare research and development are other key factors driving the apixaban market. Moreover, rising potential in emerging economies, and increasing technological advancements and modernization in the healthcare sector, will expand the market for apixaban. However, apixaban's side effects, such as an increased risk of thrombotic events and bleeding if taken too soon, are likely to limit its use, thereby hampering the market growth.

The research report covers Porter's Five Forces Model, Market Attractiveness Analysis, and Value Chain analysis. These tools help to get a clear picture of the industry's structure and evaluate the competition attractiveness at a global level. Additionally, these tools also give an inclusive assessment of each segment in the global market of Apixaban. The growth and trends of Apixaban industry provide a holistic approach to this study.

MARKET SEGMENTATION

This section of the Apixaban market report provides detailed data on the segments at country and regional level, thereby assisting the strategist in identifying the target demographics for the respective product or services with the upcoming opportunities.

By Dosage Form

  • Capsule
  • Tablet

By End-User

  • Hospitals
  • Clinics
  • Retail Pharmacies
  • Online Pharmacies
  • Others

REGIONAL ANALYSIS

This section covers the regional outlook, which accentuates current and future demand for the Apixaban market across North America, Europe, Asia-Pacific, Latin America, and Middle East & Africa. Further, the report focuses on demand, estimation, and forecast for individual application segments across all the prominent regions.

The research report also covers the comprehensive profiles of the key players in the market and an in-depth view of the competitive landscape worldwide. The major players in the Apixaban market include F. Hoffmann-La Roche Ltd, Hikma Pharmaceuticals PLC, Eisai Co. Ltd, Sanofi S.A., Yino Pharma Limited, Mylan N.V., Bristol Myers Squibb Company, Abbott Laboratories, Hebei Changshan Biochemical Pharmaceutical Co. Ltd, Nanjing Jianyou Biochemical Pharmaceutical Co. Ltd., Aspen Holdings, Fresenius Kabi AG, Pfizer Inc., Others. This section consists of a holistic view of the competitive landscape that includes various strategic developments such as key mergers & acquisitions, future capacities, partnerships, financial overviews, collaborations, new product developments, new product launches, and other developments.

In case you have any custom requirements, do write to us. Our research team can offer a customized report as per your need.

TABLE OF CONTENTS

1. PREFACE

  • 1.1. Report Description
    • 1.1.1 Objective
    • 1.1.2 Target Audience
    • 1.1.3 Unique Selling Proposition (USP) & offerings
  • 1.2. Research Scope
  • 1.3. Research Methodology
    • 1.3.1 Market Research Process
    • 1.3.2 Market Research Methodology

2. EXECUTIVE SUMMARY

  • 2.1. Highlights of Market
  • 2.2. Global Market Snapshot

3. APIXABAN - INDUSTRY ANALYSIS

  • 3.1. Introduction - Market Dynamics
  • 3.2. Market Drivers
  • 3.3. Market Restraints
  • 3.4. Opportunities
  • 3.5. Industry Trends
  • 3.6. Porter's Five Force Analysis
  • 3.7. Market Attractiveness Analysis
    • 3.7.1 Market Attractiveness Analysis By Dosage Form
    • 3.7.2 Market Attractiveness Analysis By End-User
    • 3.7.3 Market Attractiveness Analysis By Region

4. VALUE CHAIN ANALYSIS

  • 4.1. Value Chain Analysis
  • 4.2. Raw Material Analysis
    • 4.2.1 List of Raw Materials
    • 4.2.2 Raw Material Manufactures List
    • 4.2.3 Price Trend of Key Raw Materials
  • 4.3. List of Potential Buyers
  • 4.4. Marketing Channel
    • 4.4.1 Direct Marketing
    • 4.4.2 Indirect Marketing
    • 4.4.3 Marketing Channel Development Trend

5. GLOBAL APIXABAN MARKET ANALYSIS BY DOSAGE FORM

  • 5.1. Overview By Dosage Form
  • 5.2. Historical and Forecast Data
  • 5.3. Analysis By Dosage Form
  • 5.4. Capsule Historic and Forecast Sales By Regions
  • 5.5. Tablet Historic and Forecast Sales By Regions

6. GLOBAL APIXABAN MARKET ANALYSIS BY END-USER

  • 6.1. Overview By End-User
  • 6.2. Historical and Forecast Data
  • 6.3. Analysis By End-User
  • 6.4. Hospitals Historic and Forecast Sales By Regions
  • 6.5. Clinics Historic and Forecast Sales By Regions
  • 6.6. Retail Pharmacies Historic and Forecast Sales By Regions
  • 6.7. Online Pharmacies Historic and Forecast Sales By Regions
  • 6.8. Others Historic and Forecast Sales By Regions

7. GLOBAL APIXABAN MARKET ANALYSIS BY GEOGRAPHY

  • 7.1. Regional Outlook
  • 7.2. Introduction
  • 7.3. North America Sales Analysis
    • 7.3.1 Overview, Historic and Forecast Data Sales Analysis
    • 7.3.2 North America By Segment Sales Analysis
    • 7.3.3 North America By Country Sales Analysis
    • 7.3.4 United States Sales Analysis
    • 7.3.5 Canada Sales Analysis
    • 7.3.6 Mexico Sales Analysis
  • 7.4. Europe Sales Analysis
    • 7.4.1 Overview, Historic and Forecast Data Sales Analysis
    • 7.4.2 Europe By Segment Sales Analysis
    • 7.4.3 Europe By Country Sales Analysis
    • 7.4.4 United Kingdom Sales Analysis
    • 7.4.5 France Sales Analysis
    • 7.4.6 Germany Sales Analysis
    • 7.4.7 Italy Sales Analysis
    • 7.4.8 Russia Sales Analysis
    • 7.4.9 Rest Of Europe Sales Analysis
  • 7.5. Asia Pacific Sales Analysis
    • 7.5.1 Overview, Historic and Forecast Data Sales Analysis
    • 7.5.2 Asia Pacific By Segment Sales Analysis
    • 7.5.3 Asia Pacific By Country Sales Analysis
    • 7.5.4 China Sales Analysis
    • 7.5.5 India Sales Analysis
    • 7.5.6 Japan Sales Analysis
    • 7.5.7 South Korea Sales Analysis
    • 7.5.8 Australia Sales Analysis
    • 7.5.9 South East Asia Sales Analysis
    • 7.5.10 Rest Of Asia Pacific Sales Analysis
  • 7.6. Latin America Sales Analysis
    • 7.6.1 Overview, Historic and Forecast Data Sales Analysis
    • 7.6.2 Latin America By Segment Sales Analysis
    • 7.6.3 Latin America By Country Sales Analysis
    • 7.6.4 Brazil Sales Analysis
    • 7.6.5 Argentina Sales Analysis
    • 7.6.6 Peru Sales Analysis
    • 7.6.7 Chile Sales Analysis
    • 7.6.8 Rest of Latin America Sales Analysis
  • 7.7. Middle East & Africa Sales Analysis
    • 7.7.1 Overview, Historic and Forecast Data Sales Analysis
    • 7.7.2 Middle East & Africa By Segment Sales Analysis
    • 7.7.3 Middle East & Africa By Country Sales Analysis
    • 7.7.4 Saudi Arabia Sales Analysis
    • 7.7.5 UAE Sales Analysis
    • 7.7.6 Israel Sales Analysis
    • 7.7.7 South Africa Sales Analysis
    • 7.7.8 Rest Of Middle East And Africa Sales Analysis

8. COMPETITIVE LANDSCAPE OF THE APIXABAN COMPANIES

  • 8.1. Apixaban Market Competition
  • 8.2. Partnership/Collaboration/Agreement
  • 8.3. Merger And Acquisitions
  • 8.4. New Product Launch
  • 8.5. Other Developments

9. COMPANY PROFILES OF APIXABAN INDUSTRY

  • 9.1. Top Companies Market Share Analysis
  • 9.2. Market Concentration Rate
  • 9.3. F. Hoffmann-La Roche Ltd
    • 9.3.1 Company Overview
    • 9.3.2 Company Revenue
    • 9.3.3 Products
    • 9.3.4 Recent Developments
  • 9.4. Hikma Pharmaceuticals PLC
    • 9.4.1 Company Overview
    • 9.4.2 Company Revenue
    • 9.4.3 Products
    • 9.4.4 Recent Developments
  • 9.5. Eisai Co. Ltd
    • 9.5.1 Company Overview
    • 9.5.2 Company Revenue
    • 9.5.3 Products
    • 9.5.4 Recent Developments
  • 9.6. Sanofi S.A.
    • 9.6.1 Company Overview
    • 9.6.2 Company Revenue
    • 9.6.3 Products
    • 9.6.4 Recent Developments
  • 9.7. Yino Pharma Limited
    • 9.7.1 Company Overview
    • 9.7.2 Company Revenue
    • 9.7.3 Products
    • 9.7.4 Recent Developments
  • 9.8. Mylan N.V.
    • 9.8.1 Company Overview
    • 9.8.2 Company Revenue
    • 9.8.3 Products
    • 9.8.4 Recent Developments
  • 9.9. Bristol Myers Squibb Company
    • 9.9.1 Company Overview
    • 9.9.2 Company Revenue
    • 9.9.3 Products
    • 9.9.4 Recent Developments
  • 9.10. Abbott Laboratories
    • 9.10.1 Company Overview
    • 9.10.2 Company Revenue
    • 9.10.3 Products
    • 9.10.4 Recent Developments
  • 9.11. Hebei Changshan Biochemical Pharmaceutical Co. Ltd
    • 9.11.1 Company Overview
    • 9.11.2 Company Revenue
    • 9.11.3 Products
    • 9.11.4 Recent Developments
  • 9.12. Nanjing Jianyou Biochemical Pharmaceutical Co. Ltd.
    • 9.12.1 Company Overview
    • 9.12.2 Company Revenue
    • 9.12.3 Products
    • 9.12.4 Recent Developments
  • 9.13. Aspen Holdings
    • 9.13.1 Company Overview
    • 9.13.2 Company Revenue
    • 9.13.3 Products
    • 9.13.4 Recent Developments
  • 9.14. Fresenius Kabi AG
    • 9.14.1 Company Overview
    • 9.14.2 Company Revenue
    • 9.14.3 Products
    • 9.14.4 Recent Developments
  • 9.15. Pfizer Inc.
    • 9.15.1 Company Overview
    • 9.15.2 Company Revenue
    • 9.15.3 Products
    • 9.15.4 Recent Developments
  • 9.16. Others
    • 9.16.1 Company Overview
    • 9.16.2 Company Revenue
    • 9.16.3 Products
    • 9.16.4 Recent Developments

Note - In company profiling, financial details and recent developments are subject to availability or might not be covered in the case of private companies